Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Ono Pharmaceutical Co., Ltd.
Modality
Small molecule
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03176277CT.gov A Study of ONO-7475 in Patients With Acute Leukemias | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tamnorzatinib (this asset) | Ono Pharmaceutical Co., Ltd. | P1/2 | CC · 43 |
| Fludarabine | Sawa Ito, MD | P2/3 | BB |
| Cyclophosphamide | Sawa Ito, MD | P4 | BB |
| Cytarabine | Janssen Research & Development, LLC | P2/3 | BB |
| Methotrexate | SWOG Cancer Research Network | P3 | BB |
| Etoposide | SWOG Cancer Research Network | P2/3 | B |
| Busulfanum | Sawa Ito, MD | P4 | B |
| Rituximab | SWOG Cancer Research Network | P2 | B |
| Dexasone | SWOG Cancer Research Network | P2/3 | B |
+42 more in the Acute Leukemia cohort
Other indications for Tamnorzatinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P1 | CC · 47 |
| Myelodysplastic Syndrome | — | P1/2 | CC · 41 |
| Malignant Pancreatic Neoplasm | — | P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tamnorzatinib in Acute Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tamnorzatinib-acute-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →